A phase 2 neoadjuvant strategy using dual checkpoint blockade alongside chemotherapy did not improve response measures in newly diagnosed advanced high-grade serous ovarian cancer, according to the iPRIME trial results. The primary endpoint—CRS 3 rate after three cycles—was not achieved in the durvalumab plus tremelimumab arm. Secondary radiological response outcomes were also statistically non-significant when compared with chemotherapy alone. The study’s open-label design emphasizes how checkpoint additions will likely require stronger patient selection or alternative combination logic to deliver measurable benefit at this stage.